Graves’ Disease - Global Market Insights, Epidemiology and Forecast to 2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 9, 2019--The “Graves’ Disease - Market Insights, Epidemiology and Market Forecast - 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Graves’ Disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Graves’ Disease (GD) from 2017 to 2028 segmented by seven major markets.
The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2028
Graves’ Disease Epidemiology
The Graves’ Disease (GD) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by total incident population, diagnosed incident population, age-specific incident population, gender-specific incident population and by Clinical Manifestations of Graves’ disease.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to the publisher, the incident population of Graves’ Disease was estimated to be 384,538 [7MM] in 2018. United States accounts for the highest Graves’ Disease cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Graves’ Disease, followed by France with an incident population of 33,365 in 2018.
Graves’ Disease Management
This segment of the Graves’ Disease report encloses the key-cross analysis of marketed drugs.
Currently, there is no cure for Graves’ disease. The goals of treatment of Graves’ disease are to control symptoms efficiently and restore euthyroidism. The three options for treating patients with hyperthyroidism are anti-thyroid drugs (Tapazole (Methimazole), Carbimazole and Propylthiouracil) radioactive iodine ablation, and surgery. All three therapeutic options would be effective in the treatment of patients with Graves’ disease, whereas patients with toxic adenoma or toxic multinodular goiter should have either radioactive iodine therapy or surgery since these patients rarely go into remission.
In patients with toxic nodular goiter, ATDs are generally used to restore euthyroidism before definitive treatment with surgery or radioactive iodine and infrequently used as a long-term treatment when the other two therapies are contraindicated, or the patient has a short life expectancy. If drugs were used as the primary therapy, it should be given for at least 12-18 months. In case of surgery is chosen for primary therapy, near total or total thyroidectomy is the choice of surgery.
RAI therapy can be done if there are side effects of the anti-thyroid drugs, history of neck surgery or external neck radiation. Beta-blocker can be used to reduce signs and symptoms of thyrotoxicosis and to inhibit the conversion of T4 to T3 in the peripheral organs.
Graves’ Disease Market Outlook
The Graves’ Disease (GD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Antithyroid drugs are the most recommended treatment of Graves’ Disease. Methimazole is the utmost prescribed antithyroid drug in the US, Japan, Germany, France, Italy and Spain, however, Carbimazole is preferred by the UK doctors. Radioactive Iodine method has gained its importance in last few years with low dose requirement and comparatively low relapse rate. Thyroid surgery is mostly recommended in complicated cases were RAI and antithyroid drugs are not a choice.
According to the publisher, the global market of Graves’ Disease (GD) was estimated to be USD 306.3 million in 2018. The United States accounts for the largest market size of Graves’ Disease, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, Germany had the highest market size with 27.1 million in 2018, while Spain had the lowest market size of Graves’ Disease (GD). The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.
Graves’ Disease Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The entry of novel drug CFZ533, Novartis by 2024 may drive the otherwise stringent therapeutic market of the Grave’s Disease.
Graves’ Disease Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Graves’ Disease Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Graves’ Disease Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This report will help to develop Business Strategies by understanding the trends shaping and driving the Graves’ Disease market.
- Organize sales and marketing efforts by identifying the best opportunities for Graves’ Disease market.
- To understand the future market competition in the Graves’ Disease market.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yp0a1a
View source version on businesswire.com:https://www.businesswire.com/news/home/20190509005441/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/09/2019 06:18 AM/DISC: 05/09/2019 06:18 AM